Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea

International Journal of Clinical Pharmacy

Volumn 34, Issue 4, 2012, Pages 651-657

  Kang, Rae Young ^a   Lee, Juyeun ^a   Lee, Yong Hwa ^a   Lee, Hye Suk ^a   Jeong, Ji Hoon ^b   Lee, Yu Jeung ^c  

^a Seoul National University Hospital   (South Korea)

^b Chung Ang University   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

Erythropoiesis stimulating agents; Prescribing patterns; Red blood cell transfusions; Solid tumour; South Korea

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN ALFA; ERYTHROPOIETIN BETA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; DRUG USE; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SOLID TUMOR; SOUTH KOREA;

ANEMIA; ERYTHROCYTE INDICES; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; GUIDELINE ADHERENCE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867404670     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9660-0     Document Type: Review

References (21)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-34.
2. Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82:93-7.
3. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-74.
4. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-14.
5. FDA. Postmarket drug safety information for patients and providers: information on erythropoiesis-stimulating agents (ESA) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp); 16 Feb 2010. http://www.fda.gov/drugs/ drugsafety/ postmarketdrugsafetyinformationforpatientsand providers/ucm109375.htm. Accessed 9 Feb 2012.
6. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-60.
7. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-72.
8. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-32.
9. Jenkins JK. FDA news and events: erythropoiesis-stimulating agents (ESA); 26 June 2007. Available at http://www.fda.gov/ NewsEvents/Testimony/ucm110908. htm. Accessed 9 Feb 2012.
10. Korea Food and Drug Administration. ESA medicine safety letter distribution; 16 May 2007. Available at http://www.kfda.go.kr/index.kfda?mid= 394&pageNo=11&seq=4178&cmd=v. Accessed 9 Feb 2012.
11. Korea National Statistics Office. Korea Standard Classification of Disease; 1 Jan 2011. Available at http://kostat.go.kr/kssc/stclass/ StClassAction.do?method=searchDisName&classKind=5&catgrp= kssc&catid1=kssc03&catid2=kssc03b. Accessed 9 Feb 2012.
12. US Food and Drug Administration product label. Aranesp®(Darbepoetin alfa) For Injection; 16 Feb 2010.
13. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among medicare patients with cancer. J Natl Cancer Inst. 2009;101:1633-41.
14. Central Cancer Registration Office. 2008 National Cancer Statistics; 28 Dec 2010. Available at http://naver.nanet.go.kr/ SearchDetailView.do?cn= MONO1201129381&sysid=nhn. Accessed 9 Feb 2012.
15. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med. 1999;340:438-47.
16. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs. 1989;38:863-99.
17. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update. J Clin Oncol. 2007;26:132-49.
18. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27:2838-47.
19. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008;99:14-22.
20. Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion. 2009;49:895-902.
21. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer. 2011 [Epub 2011 Jan 24].